期刊文献+

乳腺癌组织VEGF-A、COX-2的表达与预后生存分析 被引量:1

Expression and prognostic analysis of VEGE- A,COX- 2 in breast cancer tissue
下载PDF
导出
摘要 目的:检测乳腺癌术后组织中VEGF-A、COX-2的表达,并进行随访,分析两者与乳腺癌患者预后的关系。方法:采用SP免疫组化法检测乳腺癌术后组织中VEGF-A、COX-2的表达,并采用Kaplan-meier法、Log-rank法和Cox比例风险模型将两者的表达与乳腺癌患者生存期进行统计分析。结果:乳腺癌术后组织VEGF-A阳性表达率明显高于乳腺良性组织(70.00%、44.11%),COX-2阳性表达率亦高于乳腺良性组织(66.67%、17.65%),同时COX-2阳性组患者的VEGF-A阳性率明显高于阴性组(80.00%、50.00%),且均有统计学意义(P<0.05);患者的临床分期、淋巴结转移状态、C-erbB-2、VEGF-A、COX-2与患者的预后有关。结论:多因素Cox回归分析显示乳腺癌组织VEGF-A、临床分期是乳腺癌患者预后的影响因素。 To study the expression of postoperative tissue VEGF - A,COX - 2,and analyze the rela-tionship with the prognosis of breast cancer. Methods:Postoperative tissue VEGF - A,COX - 2 were detected by SP immunohistochemical technique. Relation of VEGF - A,COX - 2 with breast cancer's survival was analyzed by Cox proportional hazards model,Kaplan - meier and Log - rank methods. Results:The positive expression rate of VEGF -A was higher in breast cancer than benign disease(70. 00% ,44. 11% ),the positive expression rate of COX - 2 was higher in breast cancer than benign disease(66. 67% ,17. 65% ),and the positive expression rate of VEGF - A higher in the group of COX - 2 positive(80% ,50% ),all had the statistical significance(P ﹤ 0. 05). Patient's prognosis had the relationship wih clinical stage,lymph node status,C - erbB - 2,VEGF - A and COX - 2. Conclusion:Cox multi-variate regression analysis showed that the VEGE - A of breast cancer's postoperative tissue,clinical stage are the prognostic factors in breast cancer.
出处 《现代肿瘤医学》 CAS 2014年第8期1859-1862,共4页 Journal of Modern Oncology
关键词 乳腺癌 血管内皮生长因子-A 预后 breast cancer vascular endothelial growth factor - A prognosis
  • 相关文献

参考文献2

二级参考文献27

共引文献25

同被引文献20

  • 1姜超,张峰,王少军,邹奇飞.COX-2与HIF-1α在肝癌中的表达与相关性[J].中国普外基础与临床杂志,2006,13(2):142-144. 被引量:6
  • 2Refat MS. Synthesis and characterization of ligational behavior of curcumin drug towards some transition metal ions:chelation effect on their thermal stability and biological activity [ J ]. Spectrochim Acta A Mol Biomol Spectrosc,2013,105:326 -337.
  • 3Park W, Amin AR, Chen ZG, et al. New perspectives of cureumin in cancer prevention[J]. Cancer Prey Res (Phila) ,2013,6 (5) :387 -400.
  • 4Epelbaum R, Schaffer M, Vizel B, et al. Cureumin and gemcitabine in patients with advanced pancreatic cancer [ J ]. Nutr Cancer, 2010.62(8) : 1137 - 1141.
  • 5Li ZC ,Zhang LM, Wang HB, et al. Curcumin inhibits lung cancer progression and metastasis through induction of FOXO1 [ J ]. Tumour Bio1,2014,35 ( 1 ) : 111 - 116.
  • 6Cai XZ, Huang WY, Qiao Y, et al. Inhibitory effects of cureumin on gastric cancer cells : a proteomic study of molecular targets [ J ]. Phy- tomedicine,2013,20 (6) :495 - 505.
  • 7Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms [ J ]. Cell,2011,147 ( 2 ) :275 - 292.
  • 8Watson JL, Hill R, Yaffe PB, et al. Curcumin causes superoxide anion production and p53 - independent apoptosis in human colon cancer cells[ J]. Cancer Lett,2010,297 (1) :1 -8.
  • 9Gao Y, Shi Q, Xu s, et al. Curcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cells[ J]. Int J Mol Sci ,2014,15 (9) : 15173 - 15187.
  • 10Wang P, Wang B, Chung S, et al. Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells [ J ]. RSC Adv, 2014,4 ( 66 ) : 35242 - 35250.

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部